Cargando…

Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma

BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter‐1 (HENT‐1) and deoxycytidine kinase (DCK...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Fadia, Fathy, Sara, Anani, Maha, Hassan, Adel, Attia, Fawzy, Ibrahim, Gehan, Elazab, Mona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676182/
https://www.ncbi.nlm.nih.gov/pubmed/32671914
http://dx.doi.org/10.1002/jcla.23457
_version_ 1783611718675464192
author Attia, Fadia
Fathy, Sara
Anani, Maha
Hassan, Adel
Attia, Fawzy
Ibrahim, Gehan
Elazab, Mona
author_facet Attia, Fadia
Fathy, Sara
Anani, Maha
Hassan, Adel
Attia, Fawzy
Ibrahim, Gehan
Elazab, Mona
author_sort Attia, Fadia
collection PubMed
description BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter‐1 (HENT‐1) and deoxycytidine kinase (DCK), genes involved in gemcitabine uptake and metabolism, can be beneficial in the selection of potential cancer patients who could be responding to the treatment. AIM: To study HENT‐1 and DCK gene expression in HCC patients with different protocols of treatment. METHODS: Using real‐time PCR, we analyzed expression levels of HENT‐1 and DCK genes from peripheral blood samples of 109 patients (20 controls & 89 HCC patients) between March 2015 and March 2017. All the 89 HCC patients received the antioxidants selenium (Se) and vitamin E (Vit.E) either alone (45 patients) or in combination with gemcitabine (24 patients) or radiofrequency ablation (RFA) (20 patients). RESULTS: There was a significant increase in HENT‐1 expression levels in HCC patients treated with Se and Vit.E alone as compared to controls (P ˂ .0001), while there was no significant difference between HCC patients treated with gemcitabine or RFA as compared to controls. In contrast, expression of DCK was significantly increased in all groups of HCC patients as compared to controls (P ˂ .0001). CONCLUSIONS: HENT‐1 and DCK mRNA expressions are important markers of HCC and for GEM effect and GEM sensitivity in patients with HCC. This could be beneficial in the selection of HCC patients sensitive to gemcitabine to avoid subjecting resistant patients to unnecessary chemotherapy.
format Online
Article
Text
id pubmed-7676182
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76761822020-11-24 Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma Attia, Fadia Fathy, Sara Anani, Maha Hassan, Adel Attia, Fawzy Ibrahim, Gehan Elazab, Mona J Clin Lab Anal Research Articles BACKGROUND: Several biomarkers of gemcitabine effectiveness have been studied in cancers, but less so in hepatocellular carcinoma (HCC), which is identified as the fifth most common cancer worldwide. Investigation of human equilibrative nucleoside transporter‐1 (HENT‐1) and deoxycytidine kinase (DCK), genes involved in gemcitabine uptake and metabolism, can be beneficial in the selection of potential cancer patients who could be responding to the treatment. AIM: To study HENT‐1 and DCK gene expression in HCC patients with different protocols of treatment. METHODS: Using real‐time PCR, we analyzed expression levels of HENT‐1 and DCK genes from peripheral blood samples of 109 patients (20 controls & 89 HCC patients) between March 2015 and March 2017. All the 89 HCC patients received the antioxidants selenium (Se) and vitamin E (Vit.E) either alone (45 patients) or in combination with gemcitabine (24 patients) or radiofrequency ablation (RFA) (20 patients). RESULTS: There was a significant increase in HENT‐1 expression levels in HCC patients treated with Se and Vit.E alone as compared to controls (P ˂ .0001), while there was no significant difference between HCC patients treated with gemcitabine or RFA as compared to controls. In contrast, expression of DCK was significantly increased in all groups of HCC patients as compared to controls (P ˂ .0001). CONCLUSIONS: HENT‐1 and DCK mRNA expressions are important markers of HCC and for GEM effect and GEM sensitivity in patients with HCC. This could be beneficial in the selection of HCC patients sensitive to gemcitabine to avoid subjecting resistant patients to unnecessary chemotherapy. John Wiley and Sons Inc. 2020-07-16 /pmc/articles/PMC7676182/ /pubmed/32671914 http://dx.doi.org/10.1002/jcla.23457 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Attia, Fadia
Fathy, Sara
Anani, Maha
Hassan, Adel
Attia, Fawzy
Ibrahim, Gehan
Elazab, Mona
Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
title Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
title_full Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
title_fullStr Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
title_full_unstemmed Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
title_short Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
title_sort human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in egyptian patients with hepatocellular carcinoma
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676182/
https://www.ncbi.nlm.nih.gov/pubmed/32671914
http://dx.doi.org/10.1002/jcla.23457
work_keys_str_mv AT attiafadia humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma
AT fathysara humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma
AT ananimaha humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma
AT hassanadel humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma
AT attiafawzy humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma
AT ibrahimgehan humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma
AT elazabmona humanequilibrativenucleosidetransporter1anddeoxycytidinekinasecanpredictgemcitabineeffectivenessinegyptianpatientswithhepatocellularcarcinoma